<DOC>
	<DOC>NCT01854749</DOC>
	<brief_summary>Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC</brief_summary>
	<brief_title>S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion Criteria Joined the study voluntarily and signed informed consent form; Age 1875 .Presence of at least one index lesion measurable by CT scan or MRI recurrence/metastasis of Esophageal carcinoma or gastroesophageal cancer confirmed by pathology No radiotherapy, chemotherapy or other treatments prior to enrollment PS ECOG 01 Life expectancy of more than 3 months ANC≥2×109/L，PLT≥100×109/L，Hb≥90g/L Cr≤1.0×UNL TBIL≤1.25×UNL； ALT/AST≤2.5×UNL，with hepatic metastases ALT/AST≤5.0×UNL；AKP≤2.5×UNL there is radical cure of the cancer uncontrolled chronic diarrhea and esophageal obstruction Neurological or mental abnormalities Influence of cognitive ability include central nervous system metastases Severe complication(s), e.g.,uncontrolled active infection,myocardial infarction,hypertension,arrhythmia,stenocardia Patient who has metastasis except cured skin basal cell carcinoma and carcinoma in situ of cervix accept other antitumor therapy •Female patients during their pregnant and lactation period, or patients without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ESCC</keyword>
</DOC>